Table 3.
Spatio‐temporal characteristics of Ca2+ events in permeabilized ventricular myocytes upon pharmacological intervention of the IP3R2 pathway
| WT | Amplitude (ΔF/F 0) | FDHM (ms) | Full duration (ms) | FWHM (μm) | Spark mass (a.u.) | τdecay (ms) | Time to peak (ms) |
|---|---|---|---|---|---|---|---|
| Control (25, 8) | 1.33 ± 0.12 | 18.17 ± 1.35 | 45.62 ± 5.08 | 1.95 ± 0.16 | 13.41 ± 4.44 | 18.12 ± 2.9 | 10.8 ± 1.28 |
| IP3 (22, 8) | 1.34 ± 0.15 | 18.22 ± 2.32 | 44.71 ± 7.26 | 1.96 ± 0.16 | 14 ± 4.26 | 19.82 ± 8.38 | 10.76 ± 1.14 |
| 2‐APB + IP3 (20, 3) | 1.37 ± 0.22 | 18.51 ± 2.15 | 48 ± 9 | 2.01 ± 0.14 | 15.3 ± 4.47 | 17.56 ± 4.54 | 11.5 ± 1.94 |
| XeC + IP3 (16, 3) | 1.27 ± 0.11 | 22.75 ± 3.41††† | 50.69 ± 10.35††† | 2.04 ± 0.2 | 16.55 ± 5.37 | 24.67 ± 9.48† | 13.32 ± 3.31 |
| 2‐APB (12, 3) | 1.32 ± 0.13 | 19.5 ± 3.53 | 50.25 ± 10.07 | 1.98 ± 0.2 | 13.96 ± 3.63 | 20.81 ± 8.87 | 11.83 ± 2.28 |
| XeC (16, 3) | 1.33 ± 0.25 | 22.54 ± 2.54*** | 55.28 ± 8.66*** | 2.03 ± 0.24 | 15.31 ± 5.02 | 22.34 ± 4.8** | 13.9 ± 2.88*** |
| TG | Amplitude (ΔF/F 0) | FDHM (ms) | Full duration (ms) | FWHM (μm) | Spark mass (a.u.) | τdecay (ms) | Time to peak (ms) |
|---|---|---|---|---|---|---|---|
| Control (25, 8) | 1.32 ± 0.14 | 26.22 ± 6.53 | 62.13 ± 14.89 | 1.96 ± 0.22 | 13.89 ± 4.34 | 26.86 ± 8.38 | 13.6 ± 2.71 |
| IP3 (13, 3) | 1.41 ± 0.15 | 24.79 ± 7.5 | 57.94 ± 13.57 | 1.98 ± 0.15 | 16 ± 5.22 | 32.49 ± 17.1 | 13.38 ± 5.01 |
| 2‐APB + IP3 (11, 3) | 1.32 ± 0.25 | 29.95 ± 12.8 | 68.63 ± 27.89 | 2 ± 0.12 | 15.04 ± 4.58 | 38.29 ± 27.57 | 15.64 ± 7.37 |
| XeC + IP3 (10, 3) | 1.31 ± 0.08† | 27.16 ± 8.57 | 61.99 ± 16.85 | 1.91 ± 0.17 | 13.27 ± 4.76 | 36.91 ± 19.59 | 12.35 ± 1.57 |
| 2‐APB (17, 4) | 1.31 ± 0.17 | 26.1 ± 5.27 | 57.12 ± 10.58 | 2.05 ± 0.23 | 16.34 ± 6.52 | 30.12 ± 11.52 | 13.03 ± 2.58 |
| XeC (14, 3) | 1.28 ± 0.16 | 26.93 ± 7.47 | 62.62 ± 14.65 | 2.02 ± 0.2 | 15.69 ± 5.17 | 42.3 ± 12.72 | 15.4 ± 4.73 |
Following cell permeabilization and plating, a representative line‐scan was recorded to assess Ca2+ events in control conditions. Pharmacological effects were assessed 2–4 min post‐intervention (10 μM IP3‐salt, 2 μM 2‐APB, 3 μM XeC). Parameters analysed include Ca2+ spark amplitude (ΔF/F 0), full duration at amplitude half‐maximum (FDHM, ms), full duration (ms), full width at amplitude half‐maximum (FWHM, μm), spark mass (a.u.), tau decay (τdecay, ms) and time to peak (ms) for WT and TG (** P < 0.01, *** P < 0.001 vs. control; † P < 0.05, ††† P < 0.001 vs. IP3‐salt; ANOVA followed by Dunnett's test). N and n are indicated below each condition as (n, N).